Cannabis Science Reports Success For 4th Brand New Self-Administering Cancer Patient
February 02 2012 - 11:05AM
Business Wire
Cannabis Science, Inc. (OTCBB:CBIS.OB - News) a pioneering U.S.
biotech company developing pharmaceutical cannabis (marijuana)
products, is pleased to introduce a 4th cancer patient with basal
cell carcinoma (skin cancer) on his left nostril, who is
self-administering a topical cannabis extract and having noticeable
results.
Cannabis Science has received images and documented information
from this 4th patient who has basal cell carcinoma on his left
nostril. The patient is enrolled in a photographic mole-mapping
program at the University of Colorado Hospital and is examined
annually. The last time he was examined was in October of 2011,
where his doctors found a small bump on his left nostril that was
less and 1/8" in diameter, and believed it to be basal cell
carcinoma. At that time it was too early to be certain if it was
in-fact basal cell carcinoma.
By January 2012 the small bump on his left nostril had grown
slightly and had developed a rough scaly texture similar to his
previous episodes of basal cell carcinoma. The patient began
self-administering cannabis extract oil (CT-1) topically to
the spot on his left nostril in the middle of January. The patient
immediately reported minor irritation of the spot but that the
surrounding healthy skin was not irritated. The rough scaly
texture and the minor irritation disappeared by day four of
treatment and by day nine of treatment the bump had shrunk
considerably and was almost imperceptible to the touch. In these
three images you can notice a significant reduction in the
lesion.
You can view these images on the Cannabis Science website
www.cannabisscience.com and click the 4th Patient
Button. The first photo (DJP left1.jpg) was taken on day
4 of treatment and the second photo (DJP left3.jpg) was taken after
nine days of treatment.
This patient has a history of having five different episodes of
basal cell carcinoma starting at the age of 27, and had one
malignant melanoma at age 35. He is now 46, and has suffered from
numerous severe sunburns which caused blistering and peeling. This
patient was diagnosed with dysplastic nevus syndrome (over 100
atypical moles) and has been told that he is certain to have
additional melanomas at some point in the future. Doctors have
already confirmed that he has had basal cell carcinoma on his right
jaw line, which resulted to Mohs procedure that was performed in
December of 2011.
About Cannabis Science, Inc.
Cannabis Science, Inc. is at the forefront of pharmaceutical
grade medical marijuana research and development. The second
formulations will address the needs of patients choosing to use
concentrated cannabis extracts to treat their ailments. Eventually,
all Americans will have access to a safe and effective FDA approved
medicine regardless of which state they live in. To maintain that
marijuana is a dangerous, addictive drug with no medical value is
scientifically absurd. Cannabis medicines, with no effective lethal
dose, are far safer than aspirin, acetaminophen, and most other OTC
drugs that kill thousands of Americans every year.
The Company works with world authorities on phytocannabinoid
science targeting critical illnesses, and adheres to scientific
methodologies to develop, produce and commercialize
phytocannabinoid-based pharmaceutical products. In sum, we are
dedicated to the creation of cannabis-based medicines, both with
and without psychoactive properties, to treat disease and the
symptoms of disease, as well as for general health maintenance.
Forward Looking Statements
This Press Release includes forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Act of 1934. A statement containing
works such as "anticipate," "seek," intend," "believe," "plan,"
"estimate," "expect," "project," "plan," or similar phrases may be
deemed "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995. Some or all of
the events or results anticipated by these forward-looking
statements may not occur. Factors that could cause or contribute to
such differences include the future U.S. and global economies, the
impact of competition, and the Company's reliance on existing
regulations regarding the use and development of cannabis-based
drugs. Cannabis Science, Inc. does not undertake any duty nor does
it intend to update the results of these forward-looking
statements.